- NewsCategory：
- All Company news Industry news
common105One result
-
1017
WindMIL Therapeutics and University of Californi± ≥a, Irvine Announce Collabora₽×'λtion to Collect Bone Marrow fr™φ→om Patients with Gliomas
WindMIL Therapeutics aβαnd University of California, ≠₽Irvine Announce Collab®©oration to Collect Bone ♣φMarrow from Patients with Gliomas•∞WEDNESDAY, OCTOBER 16←$✘∑, 2019WindMIL Therapeut×£ics and the University of California, Irvine (UCIπ↕§&) today announced that ™♠σthe first patients have been iden↓$tified in an investigator-spσ≤♠♦onsored study for the collection of bon→™e marrow from patients with gliomas.σδ¶ The study will evaluaφδ™$te generating marrow infiltratσφ¥ing lymphocytes (MILs™) for these p← atients through WindMIL’s proprieta↔∑ry cellular activation and e☆$₹xpansion process. The study i ∞∏←s being conducted at UCI.“Pa♣ΩΩ←tients suffering with glioblasto&♠ma are in great need←÷←÷ of new, promising treatments th™γ at might advance the current stand≥>≤₹ard of care,” said Daniela A. Bota, MD, PhD,¶& director of the UCI Health↔© Comprehensive Brain Tumor Program, senior★&§ associate dean for clinical researc<∞h, UCI School of Medicine and clinical diβ λ♠rector, UCI Sue & Bill Gross >£®$Stem Cell Research Center. “The University o>αf California, Irvine is excited λ±∞to play a key role in research that may leadβ>α to a clinical trial th↕§φat enlists the immune system in novel ways to figπ÷©£ht this terrible disease.”Gliomε₹as are the most comm♦±on of the malignant brain tumors. Gl♥±¶∑ioblastoma, the most common glioma, has a fσ¶© ive-year survival of less than 5 pe €¥rcent. Additional treatmen€<t options are urgently neede→>₩d for these patients. Ado"≥ptive immunotherapy is a possible a≠✘pproach for gliomas and ≥∏the use of MILs, a ce♣↓ll therapy that is naturally tuφ→Ω±mor-specific, is one su'β®≤ch treatment option.The bone marrow π®•is a unique niche in the immune systemδ↑∑↕ to which antigen-experienc€ ed memory T cells traff↑ ®"ic and are then maintained. WindMIL haγ s developed a proprietary process to select∑♣, activate and expand these memory T cells inλ•♥to MILs. Because memory T cell¥₽₽×s in bone marrow occur as a result&π of the immune system’s r£≤ ecognition of tumor antigens, MILs are specifical×≈♦×ly suited for adoptive cellular immunotherapy a'★nd are able to directly eradica•πte or facilitate eradication of each patien✘'t’s unique cancer. WindMIL i±ε₩ s currently studying MILs in multiple myelΩ→₹oma, non-small cell lung cancer and ₽π€squamous cell carcinoma of the head and neck, and& plans to expand into oth±∞er solid tumors.“WindMIL is looking• forward to working with the Un↕iversity of California, Irvine on ≤πthis exciting project and δ£is optimistic that MILs may offer theσ≤ potential to help patients ≠Ωφδwith these hard-to-trea★ε∑t diseases,” said Monil Shah, PharmD, MBA, Chi✘ ∏ef Development Officer at Wind₹αMIL.information sou≤δrce:pharma focus AsiaThe original li≥π☆§nk:https://www.pharmafocusasia.com/news/w >α±indmil-therapeutics-and-university-o∞↕∏f-california-irvine-announce-☆β∞&collaboration-to-collect™★-bone-marrow-from-patie™↓nts-with-gliomas2019 Asia' ¥-pacific pharma IP Leφ±ader Summit: http://en.ze↓•✘☆nseegroup.com/p/510934/will be held in Bei§∑∞<jing on Novem>&εber 14-15, and will attract morπ ∏≠e than 500 industry exp≈'≠erts from domestic and forei↑≠gn pharmaceutical companies, biotδ♣★echnology companies, governments, association© s, law firms, intellα∑→✔ectual property agents and other companies •∏to attend.Official registration and cons> ultation channels:Contact：AnnPhone: 0≥λ21-65650305Email：Marketing@zens₽←♠♠eegroup.comhttp://en.zλφ'enseegroup.com/p/51093®α∑ 4/ -
1016
CRISPR Therapeutics and KSQ Therapeutics An$±®nounce License Agreement to Advance Co•₽€¶mpanies’ Respective Cell Therapy Program"✘ s in Oncology
CRISPR Therapeutics and KSQ Therε≈apeutics Announce Lic♠♣ense Agreement to Adva∑→≠nce Companies’ Respective Cell Therapy Programs i≠♦&δn OncologyWEDNESDAY, OCTOBER 16, 201≈€♦★9CRISPR Therapeutics, a ↔₹βbiopharmaceutical company focused on creating×δ transformative gene-based medicines for se&>γrious diseases, and KSQ Therapeutic≠<♣s, a biotechnology company usin♠¥•g CRISPR technology to ena"™αble the company’s powerful drug discovery enαλ←✘gine to achieve higher probabilities of∑£ success in drug development, today announc¶β ed a license agreement whereby C♣ RISPR Therapeutics will ÷£←gain access to KSQ intellectua®≈l property (IP) for editiπ©γng certain novel gene targets in its allogeneicΩ ±φ oncology cell therapy programs, and KSQ will ★↓gain access to CRISPR The₩ rapeutics’ IP for editinγ₽ε★g novel gene targets identified by K×¥SQ as part of its current↕≥ and future eTILTM (engineered tumor infilt<♥rating lymphocyte) cell programs€∑≤. The financial terms of the agre"←σement are not being discl♣♦♥osed.“We are thrilled to gain access to CR♠>•ISPR Therapeutics’ founda₽≈>tional IP estate through ¥¥this agreement,” said David Meeker, δ♥ M.D., Chief Executive Officer at•÷✘€ KSQ Therapeutics. “Our eTILTM prograγ↑¶ms involve editing gene targets in hu↕∑man TILs that were d©♠© iscovered at KSQ by apply' €ing our proprietary CRISPRomics® approach to immu' ♦φne cells in multiple in vivo models. This agreeme¶∑♥nt clears an importan→α✔λt path for us to be able to br✘÷εing these programs through de∞ ↔velopment and commercialization, leveragin✘®g CRISPR Therapeutics’ prop"∏λrietary editing technology.”The gene ta¶δ$rgets within the scope ÷♥>of the license agreement we≤$™re identified using KSQ’s proprietary CRI×π ₹SPRomics® drug discovery engine, whδ• ich allows genome-scale, in v×βivo validated, unbiased drug disco<★ very. These specific targets wα∑ere uncovered in screens to idΩ←≈entify genetic edits ♠ that could enhance the functionality and ≠® quality of adoptive cell therap§λ₽ies in oncology.“KSQ has built an indφ™ustry-leading platfo∞∏rm to screen for novel gene targe©ε≥ts using its technolog÷φ≥★y, and has identified a ♦♦¥≤group of targets that₹₩ could help unlock the full potential o©∞εf adoptive cell therapy≤ φ in oncology,” said Samarth Ku±γ→Ωlkarni, Ph.D., Chief Executive Officer at CRISPR ₩ λ≤Therapeutics. “As a result of this license ag↓↕reement, CRISPR Therapeutics will hav≠←e the opportunity to bring these novel targets i¶•ε©nto our leading alloδ♣geneic CAR-T development platfo←α∞ rm to further strengthen our₹≈ future programs in this important tφ§herapeutic area.”information sour↓Ωce:pharma focus AsiaThe original link:https:htt≥₹ps://www.pharmafocusa✔£λsia.com/news/crispr-therape≥Ωδ©utics-and-ksq-therapeutics-announσ☆¶↔ce-license-agreement-to-advance-c¥β♥ompanies-respective-c§<∑↑ell-therapy-programs-in-oncology2$↔019 Asia-pacific pharma IP Leade☆♥r Summit: http://en.zenseegroup.com/p/510934₽>/ will be held in ↑λ™₩Beijing on N ≈•×ovember 14-15, and will attract more than↔" 500 industry experts from domestic δand foreign pharmaceutical companies, bi©βotechnology companies, government<φ★s, associations, law firms, intellectual propert≈>¥y agents and other co¥→δmpanies to attend.Official registration a₽☆♣✔nd consultation channels:Contact：AnnPhone: 021-6¥✔5650305Email：Marketing@zenseegro♣↓£♣up.comhttp://en.zenseegroup.com/p/510934/ -
1015
Shionogi enters into a new license agreem÷✔ent and research collabor₩£™πation for the treatment of mycobacterial ≥÷diseases with Hsiri ★¶ε∑Therapeutics, Inc.
Shionogi enters into a new license agreemen>≤↓t and research collaboration for th♥®®e treatment of mycobacterial dis★₹★eases with Hsiri Therap≠←™eutics, Inc.MONDAY, OCTOBER 14, 2019™¶Shionogi & Co., Ltd. today ann÷>←ounced that it has enter←♥σed into a new license agreement with Hsiri ¶&₹Therapeutics, Inc. (£→©Head Office: Media, PA, USA; President and λ₩≈'CEO: William Claypool, M.D.; hereafter "Hsiri♣✘₹") regarding a collaborative reseaε≈rch and development pr™↑ogram to discover and develop additional no'¥vel therapeutics for non-tu≠ berculous mycobacterial✔δ≥₽ (NTM) diseases and tuberculosis (TB). This n ↑ew collaboration will include technology ♣<♠that complements Shionogi's ear™ lier collaboration arrangement with Hsiri.The ♦ ♥new technology to be licensed✘ק from Hsiri has a novel mechanis→≥®m of action, will be♣→☆ complementary to Sh$↑₽ ionogi's current research with Hsiri, and is§♥ anticipated to be more ef ¥•↑fective than current therapies for mycobacteri∞©£al infections. Shionogi's strength in> ®λ small molecule drug discovery a☆δ"≤nd development in the antiba®✘¥φcterial area will support development of H δ÷siri's innovative therapeutics in this collabor£¥ative program. Under the terms of™₽ this agreement, Shionogi will have±< exclusive worldwide rights to d×₩evelop, manufacture, and comme •rcialize the compounds generated ≠'δ≥from the collaboration. Hsiri will recei←§φ€ve an upfront license fδ≤'×ee, potential development milestones, and ro↑♦γyalty payments based on sales fr↑♠om Shionogi.It is reported that the ©✔number of patients suffering from NTδ♦M diseases has been increasing, α←×especially in developed countries, in ₽∏↕™recent years. There is a medical need ♠€★to develop novel anti-NTM drugs ≥÷ because of the long d™∏§≈uration of treatment and insufficie$'nt treatment outcome of current¥βπγ therapeutics. TB is one o<'f the three major infectious ₩≈€♦diseases in the world, and new ♥™↔ cases of TB are estimated to be 10.γ4 million/year. Multidrug-resistant T$®B (MDR-TB) and extensively drug-→resistant TB (XDR-TB) have become a major ≥¶public health concern, and≈₩✘ novel drugs for MDR-TB an→ ¶d XDR-TB are anticipate$•₩¶d.Shionogi's research and d♦≤evelopment targets infec✔☆tious disease as one of its priority ar∑λeas, and Shionogi have positioned "protectε¶ ing people from the threat of infectious disα™eases" as one of its social mission♣δ¶♥ targets. Through this cooperation, Shio© ∏∑nogi strives constant<<ly to bring forth in∏γβnovative drugs for the treatment of inf✘δ₹♥ectious diseases, to protect the h™÷ealth of patients we se÷π•±rve.information source:pharma focus ♥¥÷∏AsiaThe original link:htβ♠ λtps:https:https://www.pharmafocusasia.com/news/®₩∏✘shionogi-enters-into-a-new-license-agreement-an&λd-research-collaboration-for-the-treatment-of-myc€φobacterial-diseases-wi± th-hsiri-therapeutics-inc2019 Asia-pacificφ∏ pharma IP Leader Summit: http://en.zenseegr壶oup.com/p/510934/ wilπ↓>l be held in Beijing on&n₹¥γbsp;November 14-15, and will✘®± attract more than 500 industry experts from doλ<↑≠mestic and foreign ph≥•&armaceutical companies, biotechnology companies,☆÷ governments, associations, law firms,βα intellectual property agents ™♣and other companies to attend.Official registra≠βεtion and consultation channels:Contact：A¶€β¶nnPhone: 021-65650305Email：Marketing@zenseegro♦€≥γup.comhttp://en.zenseegroup.com/p/510934™Ω/ -
1014
Advaxis and UCLA Enter Collaborat®"✔•ion for Glioblastoma Immunotherapy Discoveπ♦ry Research
Advaxis and UCLA Enter Collaboraεtion for Glioblastoma Immunotherapy Discover<↕ y ResearchFRIDAY, OCTOBERδ↑ 11, 2019Advaxis, Inc., a clinical-stage biote♥↔chnology company focused on the discovery, deve©↓φ÷lopment and commercializatio∑Ω§n of immunotherapy products, today announced a re'β™★search collaboration agreement ₽÷≤φwith the University of California Losφ₩™ Angeles (UCLA) to conduct preclin↕ ical studies evaluatinπ✘g the Company’s Lm technol↔≈₩ogy in mouse tumor models oγ≥ f glioblastoma multiforme (GBM). Specifically, t≤♦he collaboration with Dr. Vaithi Arumugaswa±mi’s group at UCLA’s Department of' Molecular and Medical Pharmacology wilγ©↔←l investigate anti-tumor immunity and anti-tumo→σ☆r responses generated by Lm v÷& δaccines that express di∏verse glioblastoma neoantigens.“W♥ e are excited that Dr. Arumugaswami and his coσ✔lleagues at UCLA will investi™$>gate the potential of our Lm technolog¶©™y platform in GBM, one of the deadlies↑↕ t cancers,” said Andres Gutierrez, Ex'≥ ecutive Vice President and Chief Medical <♦Officer of Advaxis. “↓®≠Contrary to other tumor types, GBM has no©γ♠ t seen much success in targeting by immunot↕φ£>herapeutic agents due to a low tumor mu±♥♣δtation burden, high tumor heterogeneity and pr≤π↕esence of the blood brain barrier, am←≠©ong other factors. Hence, Dr. &"→ Arumugaswami’s characterization ★δ< of the neoantigen landscape and immune resp₩↕✔•onses to Lm- construct←<s may lead to the deveεγ♣★lopment of novel ther'€αapies with clinical activity in this elu↕↑£♦sive cancer.”informat≥β"ion source:pharma focus AsiaThe original lin∏φ₽♦k:https:https:https://www.pharmafocusasi≥€≈a.com/news/advaxis-and-ucla-e≥ $↓nter-collaboration-for-glioblastomaβσ±€-immunotherapy-discoverα>≤•y-research2019 Asia-'>pacific pharma IP Leader Summit: http://§™≠>en.zenseegroup.com/p/510934/will be held in&π₹ nbsp;Beijing on ©™↔₩;November 14-15, and & ∑≤will attract more than 500 industrα♠•y experts from domestic and foreig±&Ω✔n pharmaceutical companies, b≤<iotechnology companies, governments, associa →♣☆tions, law firms, intellectual propert♣₩≈↑y agents and other companies to atteπ®nd.Official registration and coε©↓nsultation channels:Contact：A↓εnnPhone: 021-65650305Email：Mar π≈✔keting@zenseegroup.c®&♣∑omhttp://en.zenseegroup.com/p/510934λ♦/ -
1011
Viela Bio Enters Strategiβ>c Collaboration with Mitsubishi Tanabe Pha≠ βrma to Develop and Commerci$§alize Inebilizumab for Autoimmune Diseases in Jap←&δ≤an and Other Asia Regions
THURSDAY, OCTOBER 10, 201§σ™'9Viela Bio, Inc. and Mitsubishi Tanabe Pharma Cor✘≈poration (“MTPC”) today announcedγ↑✘ a collaboration focused on the d&↑ε¶evelopment and commercialization of inebilizu↓mab – Viela’s humanized anti-CD1π¶λ9 monoclonal antibody –≈∞ → in nine Asia regions f•→or neuromyelitis optica spectr✔φ₽um disorder (NMOSD), as well as other pγotential future indications.“This partnership addγ£s to our ability to commercia≈∑γ™lize inebilizumab globallββ$λy, subject to regulatory a↑Ωpproval,” commented Bing Yao, Ph.D., Viela’÷≈≥s Executive Chairman and Chief Execε±♦$utive Officer. “As a well-established pha±πrmaceutical company § ≥®in Japan, Mitsubishi Tanabe has stro>®λng product development and commerciali∞>•∞zation capabilities in Asia, and ♣€↓we believe, is an ideal parπ>γ™tner for expanding inebilizumab’s potentia×π★l reach to thousands of addit©Ω®δional patients in need of ₽₩viable treatments, with NMOSD as an initia♥ ₹σl indication.”Under terms of the collabora→÷tion, Viela will receive an up-froα±nt licensing fee of $30 million as₽✘ well as additional payments contingent€λ • on certain developmen¥↓γ$t and commercial milestones©♠'≈, plus payments based, in part, on sales r> σevenue. MTPC will be responsible ¶λ₽↑for leading development and com™•γγmercialization of inebilizumab in Ja♦ pan, Thailand, South Korea, Indonesia, Vie★♣tnam, Malaysia, Philippines, Singapore, a®Ωnd Taiwan.“Our organizatio₽✔↓n is delighted to partner with Viela to develop a×πnd commercialize their promising pr<oduct candidate inebilizumab★•' for autoimmune and in₩✘≤flammatory diseases,” said Masayuki ♦Mitsuka, MTPC President &a✔mp; Representative Director. ☆ ≤“Inebilizumab is an excit♥ing product candidate that, based on the resultsφγ from the N-MOmentum pivoε ↔tal study, is well-positioned to provide mea>δΩ©ningful benefit for patients with N©π MOSD, and potentially ad₽"₩ditional diseases, subject to regulatory ¥≠εδapproval. We are excπ₽ited to work with Viela to advaλ₹nce inebilizumab in Japan and other Asia r®∞egions, and look forward to φ∞a productive partnership between our compaα¶'£nies.”The U.S. Food and Drug Administration£→ (FDA) recently accepted for review Viela’s×γ± Biologics License Application (BLA) for'♠♠♠ inebilizumab for the treatment o≠∑α"f NMOSD. information source:pharma focu<§s AsiaThe original link:https:https://www.¶♣≤pharmafocusasia.com/news/viela-bio-enters-s↔↔$trategic-collaboration-with-mitsubishi-tδ anabe-pharma-to-develop-and-comme♦λ₩↓rcialize-inebilizumab-for-✘←autoimmune-diseases-in-←₹japan-and-other-asia-regions'¥÷"2019 Asia-pacific pharma IP Leader Summit: λ★http://en.zenseegroup.com/p/510934/will be held₩ in Beijing on No₹♥vember 14-15, and will attrε'act more than 500 industry₹♠£ experts from domestic and foreign phar↔₽∏maceutical companies₹≥, biotechnology companies, government ↓↑s, associations, law firms≈¥π®, intellectual property age☆™nts and other companies to attend.Official regist← ∏ration and consultation channels:≥↕™γContact：AnnPhone: 021-6€®5650305Email：Marketing@zenseegroup.comhttp://e↔↔n.zenseegroup.com/p/510934/
Contact Us
Zensee_Daystar online
© 2011-2016